Overall, our findings can contribute to guidance for rational GLP-1RA usage in Asia,suggesting that GLP-1 analogues are desirable for T2D patients with normal BMI as well as for those with overweight/obesity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.